文献速递炎症性肠病

新诊断炎症性肠病五年临床病程及生物制剂治疗、住院和手术的预测因素

Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five-Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2026-10-11

这项西班牙前瞻性多中心起始队列纳入2017年新诊断的3301例成人IBD患者并随访5年。诊断后5年内30%使用生物制剂/JAK抑制剂,34%至少住院一次,9%接受手术;CD患者累积发生率更高。生物制剂/JAKi与CD和UC住院风险降低相关,但与CD腹部手术风险无关,与UC手术风险增加相关。

要点

  • 新诊断IBD后5年内30%使用生物制剂/JAKi,34%住院,9%手术。
  • CD患者的生物制剂/JAKi使用、住院和手术累积发生率均高于UC。
  • 生物制剂/JAKi与CD和UC住院风险降低相关,但未降低CD腹部手术风险。

核心结论

  • 新诊断IBD后5年内生物制剂/JAKi使用率高于既往报告;该治疗与住院风险降低相关,但在当前临床实践模式下未转化为腹部手术风险降低。

研究设计与样本

  • 西班牙前瞻性多中心新诊断IBD队列注册研究,2017年纳入成人CD、UC或IBD-U患者并随访5年。
  • 共纳入3301例患者:CD 1526例,UC 1633例,IBD-U 142例;诊断中位年龄43岁(IQR 31-56),约50%为男性。

主要发现

  • 诊断后5年内,30%接受生物制剂或JAK抑制剂(JAKi),34%至少住院一次,9%接受手术。
  • CD患者的生物制剂/JAKi治疗、住院和手术累积发生率均高于UC患者。
  • 生物制剂/JAKi使用与更侵袭性CD表型、更广泛UC病变范围和更年轻诊断年龄相关。
  • 生物制剂/JAKi治疗与CD住院风险降低相关(HR=0.4,95%CI 0.2-0.6),与UC住院风险降低相关(HR=0.5,95%CI 0.2-0.9)。
  • 生物制剂/JAKi与CD腹部手术风险无关,但与UC手术风险增加相关(HR=11.9,95%CI 4.6-30.4)。

临床怎么用

  • 对新诊断IBD患者应评估CD表型、UC病变范围和诊断年龄以预判生物制剂/JAKi使用及住院风险。
  • 生物制剂/JAKi可降低IBD住院风险,但临床决策时不应预期其必然降低CD腹部手术风险。
  • UC患者使用生物制剂/JAKi时需关注手术风险增加的关联,结合临床实践模式个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aimed to describe the characteristics of newly diagnosed inflammatory bowel disease (IBD) patients and to analyse their clinical course within the first 5 years after diagnosis, including the need for surgery, hospitalisations and treatments. METHODS: This prospective and large multicentre incident cohort registry in Spain enrolled adults diagnosed with Crohn's disease (CD), ulcerative colitis (UC) or unclassified IBD (IBD-U) in 2017 and followed them for 5 years. RESULTS: A total of 3301 patients were enrolled: 1526 with CD, 1633 with UC and 142 with IBD-U. Their median age at diagnosis was 43 years (interquartile range 31-56) and approximately 50% were male. Within 5 years post-diagnosis, 30% received biologics or JAK inhibitors (JAKi), 34% were hospitalised at least once and 9% underwent surgery. The cumulative incidence of biologic/JAKi treatment, hospitalisations and surgeries was higher among CD patients. Use of biologics/JAKi correlated with a more aggressive CD phenotype, greater UC extent and younger age at diagnosis. Biologics/JAKi treatment was associated with lower hospitalisation risk in both CD (Hazard ratio [HR] = 0.4, 95% confidence interval [CI] = 0.2-0.6) and UC patients (HR = 0.5, 95% CI = 0.2-0.9). However, it was not associated with the risk of abdominal surgery in CD but was linked to an increased risk of surgery in UC (HR = 11.9, 95% CI = 4.6-30.4). CONCLUSIONS: This large multicentre cohort demonstrated a higher use of biologics/JAKi during the first 5 years after IBD diagnosis than previously reported. Treatment with biologics/JAKi was associated with reduced risk of hospitalisation. However, under current clinical practice patterns, this therapeutic approach did not translate into lower risk of abdominal surgery.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Garre A, Nuñez Ortiz A, Rubio S, et al. Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five-Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2026. PMID: 42860841. doi:10.1111/apt.70987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。